Acessibilidade / Reportar erro

Translocation t(8;21)(q22;q22) in Acute Myeloid Leukaemia

Translocação t(8;21)(q22;q22) em Leucemia Mielóide Aguda

IMAGENS EM HEMATOLOGIA IMAGES IN HEMATOLOGY

Translocation t(8;21)(q22;q22) in Acute Myeloid Leukaemia

Translocação t(8;21)(q22;q22) em Leucemia Mielóide Aguda

Lidiane C. Rueda; Maristela Zocca; Gislaine B. Oliveira; Carmen S. P. Lima

Haematology and Haemotherapy Centre of Campinas, State University of Campinas, Campinas, São Paulo, Brazil

Correspondence Correspondence to Carmen Silvia Passos Lima, MD, PhD Hemocentro – Unicamp – Cidade Universitária "Zeferino Vaz" Caixa Postal 6198, Cep: 13083-970 – Campinas, SP – Brazil Phone: + 55 19 3788-8740 – Fax: + 55 19 3788-8600

The reciprocal translocation between chromosomes 8 and 21 with breakpoints in 8q22 and 21q22 was first reported by Rowley, in 1973, 1 in a subgroup of patients with acute myeloid leukaemia (AML).

It soon turned out that most t(8;21)(q22;q22) cases were LMA subtype M2; only occasional leukaemias with this abnormality have been classified as subtype M1 or, even more rarely, subtype M4. 2

The 8;21-translocation appears to be more frequent in the young and is rare beyond the age of 50 years. 3 It is the most frequent structural anomaly in AML overall, occurring in nearly 15% of all FAB-classified cases and in 40% of AML diagnosed as M2. 4

The translocation results in the generation on the derivative chromosome 8 of a consistent hybrid gene, ETO-AML-1, 5 that encodes a novel message for haematopoietic cell proliferation.

Since high complete remission rates as well as their duration 6 have generally been found in AML subtype M2 patients with t(8;21)(q22;q22) treated with conventional chemotherapy regimens, this translocation has been considered as a prognostic indicator of favourable outcomes.

Herein, we present for educational purposes, the images obtained from bone marrow cytological and cytogenetics analyses (Figures 1 and 2) of a AML subtype M2 case seen at the Haematology and Haemotherapy Centre of the State University in Campinas.



References

1. Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16:109-112.

2. Groupe Francais de Cytogénétique Hématologique. Acute myelogenous leukaemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogénétique Hématologique. Cancer Genet Cytogenet 1990;44:169-179.

3. Petkovic I, Konja J, Nakic M. Cytogenetic analysis in children with acute non-lymphocytic leukemia. Cancer Genet Cytogenet 1992;58:155-159.

4. Mitelman F, Heim S. Quantitative acute leukemia cytogenetics. Genes Chromosomes Cancer 1992;5:57-66.

5. Downing JR, Head DR, Cursio-Brint AM et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21)(q22;q22) translocation. Blood 1993; 81:2860-2865.

6. Marosi C, Köller U, Köller-Webber E et al. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 1992;61:14-25.

Recebido: 16/12/2003

Aceito após modificações: 02/01/2004

Avaliação: Editor e dois revisores externos.

Conflito de interesse: não declarado

  • Correspondence to

    Carmen Silvia Passos Lima, MD, PhD
    Hemocentro – Unicamp – Cidade Universitária "Zeferino Vaz"
    Caixa Postal 6198, Cep: 13083-970 – Campinas, SP – Brazil
    Phone: + 55 19 3788-8740 – Fax: + 55 19 3788-8600
  • Publication Dates

    • Publication in this collection
      19 July 2004
    • Date of issue
      Mar 2004
    Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular R. Dr. Diogo de Faria, 775 cj 114, 04037-002 São Paulo/SP/Brasil, Tel. (55 11) 2369-7767/2338-6764 - São Paulo - SP - Brazil
    E-mail: secretaria@rbhh.org